The EPS beat and raised guidance, combined with the debt repayment, signal strong operational momentum and improving financial health. The stock should react positively. Key catalysts to watch: continued LINZESS prescription demand growth and enrollment updates for the STARS-2 apraglutide trial.
Drug in focus
Linzess
● Neutral Named in this 8-K- Impact
- Phase
- Approved / marketed (Phase 3 completed for the pediatric ages 2–5 sNDA)
- Time to market
- Already marketed in the U.S. since FDA approval in 2012; the only pending item was the pediatric (ages 2–5) label-expansion sNDA decided around its May 24, 2026 PDUFA date.
- Next catalyst
- None dated
What to watchFor ABBV holders, Linzess is immaterial to the thesis, treat it as steady, profitable co-marketed revenue, not a catalyst. Watch the 2026-08-06 IRWD Q2 earnings print (the co-commercialization partner) for Linzess U.S. net-sales momentum and any update on the ages 2–5 pediatric label decision from the May 2026 PDUFA, which the local data does not yet record as approved or rejected.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 6 $4.26entry
- T+1 · 3mo ago +1.41%α +0.80% · $4.32
- T+5 · 3mo ago −4.23%α −5.44% · $4.08
- T+20 · 3mo ago +0.70%α +0.10% · $4.29
- T+60 · 18d ago −17.84%α −16.17% · $3.50
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ironwood Pharmaceuticals reported Q2 2026 GAAP EPS of $0.31, beating the $0.28 consensus by 10.7%, on revenue of $113.0M (slightly below the $114.7M estimate). The company raised full-year 2026 guidance: LINZESS U.S. net sales to $1.15-$1.20B (from $1.125-$1.175B), total revenue to $460-$485M (from $450-$475M), and adjusted EBITDA to >$310M (from >$300M). The beat was driven by strong LINZESS performance (14% YoY net sales growth, 78% commercial margin) and the company repaid its $200M convertible notes with cash on hand, strengthening the balance sheet. The STARS-2 Phase 3 trial for apraglutide is now actively recruiting patients.
Key Financial Metrics
Key Facts
- GAAP EPS of $0.31 beat consensus of $0.28 by 10.7%
- Total revenue of $113.0M vs consensus of $114.7M (slight miss)
- LINZESS U.S. net sales of $282.3M, up 14% YoY
- Full-year 2026 guidance raised: LINZESS net sales to $1.15-$1.20B, total revenue to $460-$485M, adjusted EBITDA >$310M
- Repaid $200M convertible notes in full with cash on hand
- STARS-2 confirmatory Phase 3 trial for apraglutide now actively recruiting patients
- GAAP net income of $51.3M vs $23.6M in Q2 2025
- Adjusted EBITDA of $83.0M vs $50.1M in Q2 2025
- Cash from operations of $58.3M vs $15.1M in Q2 2025
Financial Impact
EPS beat of $0.03 (10.7%) on consensus of $0.28; revenue slightly below consensus by $1.7M (1.5%). Full-year guidance raised by $25M on LINZESS net sales and $10M on total revenue.
Risk Factors
- LINZESS net price improvement may not be sustainable if gross-to-net rebate timing normalizes
- Apraglutide STARS-2 trial carries clinical and regulatory risk
- High leverage ($385M revolver) despite debt repayment
- Cash balance dropped to $79.1M from $215.5M at year-end 2025 due to debt repayment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-091625 |
| Document: tm2622244d1_8k.htm | 0001104659-26-091625 |
| Document: 0001104659-26-091625-index-headers.html | 0001104659-26-091625 |
| Document: 0001104659-26-091625-index.html | 0001104659-26-091625 |
| Document: 0001104659-26-091625.txt | 0001104659-26-091625 |
| 8-K Data (Synthetic) | 0001104659-26-091625 |
Track record
13 reports on IRWD
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +20.35% at T+5 after the Nov 5, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.88 Now $4.85 −0.51% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $4.84 Now $4.85 +0.21% settles Dec 15
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.81 Now $4.85 +0.83% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $4.81 Now $4.85 +0.83% settles Dec 9
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $4.03 Now $4.85 +20.35% settles Dec 4
- Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $3.61 Now $4.85 +34.35% settles Nov 25
- Oct 16, 20264w ago 8-K Neutral 3/10 Entry $3.50 to $4.85 Now $4.85 +38.57% ▲ +38.57% +39.73% vs SPY
- Aug 6, 202614w ago 8-K Bullish 7/10 Viewing Entry $4.26 to $4.29 Now $4.85 +13.85% ▲ +0.70% +0.10% vs SPY
- May 13, 202626w ago 8-K Mixed 6/10 Entry $3.68 to $3.63 Now $4.85 +31.79% ▼ −1.36% −0.75% vs SPY
- May 7, 202627w ago 8-K Bullish 7/10 Entry $4.17 to $3.24 Now $4.85 +16.31% ▼ −22.30% −25.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers